# StartEngine

除Reg CF外，还能依据规模更大的Regulation A+豁免（最高7500万美元）募资，曾为Eliaz Therapeutics及Frontier Bio主办募资活动，后者开发实验室培育人体组织模型及组织工程血管移植物，旨在作为比动物实验更安全的临床前替代方案。

Source: https://cn.bioecon.ru/companies/startengine/
Updated: 2026-07-04

- 国家: United States

## 可核验事实

| 事实 | 数值 | 来源 |
| --- | --- | --- |
| 融资 | 目标金额$3 million（Reg CF众筹） (2026-06-11) | https://investcf.eliaztherapeutics.com/, https://www.globenewswire.com/news-release/2026/06/11/3310835/0/en/Eliaz-Therapeutics-Launches-Reg-CF-Raise-to-Advance-First-Device-Targeting-Sepsis.html |
| 融资 | 迄今累计募集$8 million (2026-06-11) | https://www.globenewswire.com/news-release/2026/06/11/3310835/0/en/Eliaz-Therapeutics-Launches-Reg-CF-Raise-to-Advance-First-Device-Targeting-Sepsis.html |
| 员工人数 | 10人（员工及承包商） (2026-04-29) | https://www.sec.gov/Archives/edgar/data/2042609/000187285626000133/eliazformcar.pdf |
| 营收 | $302,481 (2025-12-31) | https://www.sec.gov/Archives/edgar/data/2042609/000187285626000133/eliazformcar.pdf |
| 监管批准 | 获授予 FDA 突破性医疗器械认定 (2025-01-01) | https://eliaztherapeutics.com/investors/, https://invest.eliaztherapeutics.com/startengine/, https://www.globenewswire.com/news-release/2026/06/11/3310835/0/en/Eliaz-Therapeutics-Launches-Reg-CF-Raise-to-Advance-First-Device-Targeting-Sepsis.html, https://www.startengine.com/offering/eliaz-therapeutics |
| 总部 | 美国加利福尼亚州圣罗莎 | https://www.sec.gov/Archives/edgar/data/2042609/000187285626000133/eliazformcar.pdf |

独立来源: eliaztherapeutics.com, globenewswire.com, invest.eliaztherapeutics.com, investcf.eliaztherapeutics.com, sec.gov

## 技术

- [生物技术众筹与散户投资](https://cn.bioecon.ru/technology/crowdfunding-retail-investment-biotech/)